Biohaven Pharmaceutical Holding Company Ltd. believes Nurtec ODT (rimegepant) is poised to become the market-leading oral calcitonin gene-related peptide (CGRP) antagonist on the market after a successful early launch in the midst of the COVID-19 pandemic. Nurtec ODT generated $65m in 2020, reflecting about nine months of sales after the drug launched that March, the company reported on 1 March.
The launch exceeded management's expectations with around 337,000 prescriptions written for Nurtec OTD in 2020 by 24,000 unique prescribers.






